EverHint Signal — EMA10 × Price × MACD — January 06, 2026

What This Signal Is (Quick)

EMA10 × Price × MACD is an experimental momentum strategy that requires two bullish crossovers to happen simultaneously on the same day:

1. Price crosses above EMA10 from below

   • Yesterday: Price was below or at the 10-day exponential moving average
   • Today: Price breaks above EMA10
   • Signals: Short-term trend reversal from down to up

2. MACD Line crosses above Signal Line from below

   • Yesterday: MACD Line was below or at the Signal Line
   • Today: MACD Line crosses above Signal Line
   • Confirms: Bullish momentum shift at the indicator level

Double Confirmation = Higher Quality

This dual-crossover requirement filters for stocks where both price action AND momentum indicators confirm a bullish shift—meaning fewer signals (typically 10-30 per day) but higher conviction setups.

Key Characteristics:

• Buy signals only: This strategy generates only bullish signals (no sell signals)
• Fewer but higher quality: Dual confirmation = 5-30 signals/day vs. 20-40 for single-indicator strategies
• Fast response: EMA10 is sensitive—catches early moves without lag of slower MAs
• Momentum context: MACD adds underlying momentum confirmation beyond just price
• Swing trading focus: Ideal for 1-4 week holding periods

This is an experimental scanner. Signals are for educational purposes and backtesting—not trade recommendations. Always do your own due diligence.

How We Ranked Today (Reader Version)

We ranked all buy signals by RSI(14) from lowest to highest. For buy signals, lower RSI = more oversold = better risk/reward when crossed up (buying into strength from oversold levels).

We've also overlaid:

• Insider Net (USD): Net insider buying or selling over 90 days (P-S only, excluding awards/exercises)
• Days → Earnings: Time until next earnings report (event risk or potential catalyst)

Ranking Logic:

• RSI < 35: Very oversold—bouncing from extreme weakness
• RSI 35-50: Moderately oversold to neutral—healthy pullback bounce
• RSI 50-70: Overbought territory—momentum continuation but higher risk
• RSI > 70: Extremely overbought—late-stage momentum, high reversal risk

Important: Signals are for educational use and backtesting. Not financial advice.

📈 Buy-Side Signals

We scanned 27 dual-crossover buy signals today. Here are all signals ranked by RSI (lowest = most oversold = highest rank):

Field Notes:

Very Oversold (RSI < 35) — Top 3:

• PVH (RSI 31.7): Apparel company (Calvin Klein, Tommy Hilfiger) bouncing from oversold levels. Price crossed above EMA10 at $70.01, MACD confirmed. No insider activity. Earnings in 83 days (low risk). Below SMA200 ($75.98)—still in downtrend, but dual crossover suggests short-term bounce.
• AAP (RSI 34.8): Auto parts retailer bouncing from $41.36. Price crossed EMA10, MACD confirmed. Launched new "ARGOS" oil/fluids brand (Jan 6)—brand expansion. Earnings in 50 days. Below SMA200 ($49.31)—downtrend bounce.
• VAC (RSI 37.1): Marriott Vacations at $62.54, crossing up from oversold. MACD confirmed bullish momentum. Earnings in 50 days. Below SMA200 ($66.38)—downtrend reversal attempt.

Moderately Oversold (RSI 35-50) — Key Picks:

• PANW (RSI 41.9, $185.86): Palo Alto Networks bouncing from pullback. "Plunges 14% in 3 Months" (Zacks)—but dual crossover suggests reversal. "3 Cybersecurity Stocks You Can Buy and Hold for the Next Decade" (The Motley Fool). Insider selling: Director sold $142K. Earnings in 37 days. Below SMA200 ($192.41)—downtrend but showing momentum.
• DGX (RSI 41.4, $180.46): Quest Diagnostics crossing up. Insider selling: CEO sold $916K, director sold $240K (total -$1.5M). Earnings in 23 days (Jan 29—event risk approaching). Above SMA200 ($177.32)—uptrend confirmation.
• AI (RSI 43.2, $14.15): C3.ai bouncing from lows. "Is C3.ai Stock a 'Buy' or 'Sell' In 2026?" (GuruFocus)—mixed sentiment. Heavy insider selling: CEO sold $3.6M. Earnings in 50 days. Below SMA200 ($19.91)—long downtrend, high risk.
• LH (RSI 45.3, $260.40): Labcorp Holdings crossing up at $260.40. No insider activity. Earnings in 30 days. Above SMA200 ($258.08)—confirming uptrend.
• FLO (RSI 46.0, $10.79): Flowers Foods (bread/bakery) crossing up. Dave's Killer Bread launches new breakfast bars (Jan 6)—product expansion. Earnings in 31 days. Below SMA200 ($14.75)—downtrend.
• DE (RSI 48.3, $485.98): Deere & Company (farm equipment) crossing up. No insider activity (only awards). Earnings in 37 days. Above SMA200 ($483.40)—uptrend confirmation.
• FOUR (RSI 49.0, $65.88): Shift4 Payments crossing up. "Announces Third Dividend Date for Mandatory Convertible Preferred Stock" (Jan 5)—$1.50/share dividend Feb 2. Insider selling: CEO sold $440K. Earnings in 42 days. Below SMA200 ($83.46)—downtrend bounce.

Neutral to Overbought (RSI 50-70) — Momentum Plays:

• ISRG (RSI 70.7, $592.85): Intuitive Surgical is the most overbought signal (RSI 70.7). Price at $592.85 crossed above EMA10, MACD confirmed. Heavy insider selling: CEO sold $13.9M. Earnings in 16 days (Jan 22)—HIGH RISK. Above SMA200 ($511.74)—strong uptrend. This is a late-stage momentum chase—high risk, high reward.
• CIEN (RSI 67.6, $254.19): Ciena (optical networking) with high RSI. Insider selling: CEO sold $1.6M. Earnings in 63 days. Above SMA200 ($121.89)—strong uptrend.
• SYK (RSI 64.5, $366.39): Stryker (medical devices) with elevated RSI. Earnings in 21 days (Jan 27—event risk). Above SMA200 ($374.50)—uptrend.
• GSK (RSI 63.0, $50.56): GSK pharma crossing up. Japan approved Exdensur for severe asthma (Jan 6)—new drug approval. Earnings in 29 days. Above SMA200 ($41.31)—strong uptrend.
• CYTK (RSI 55.6, $64.60): Cytokinetics biotech crossing up. Insider selling: Officers sold $4.1M (heavy). Earnings in 51 days. Above SMA200 ($46.24)—uptrend.

Recent Headlines (Buy-Side Signals):

PANW (Palo Alto Networks):

• "Rises Higher Than Market: Key Facts" (Zacks)—stock up 2.05% to $185.86
• "PANW Plunges 14% in 3 Months: Should You Hold or Fold the Stock?" (Zacks)—slowing growth but large AI-driven deals
• "3 Cybersecurity Stocks You Can Buy and Hold for the Next Decade" (The Motley Fool)—long-term buy thesis
• "Can Platformization Continue Fueling PANW's NGS ARR Growth?" (Zacks)—platform strategy driving NGS growth
• Insider selling: Director sold $142K

AAP (Advance Auto Parts):

• Launched "ARGOS" new oil/fluids brand (Jan 6)—designed for quality and affordability
• No insider activity

AI (C3.ai):

• "Is C3.ai Stock a 'Buy' or 'Sell' In 2026?" (GuruFocus)—mixed sentiment after tough 2025
• "Outpaced the Stock Market Today" (Zacks)—up 1.09% to $13.90
• Heavy insider selling: CEO sold $3.6M

FOUR (Shift4 Payments):

• Announces Third Dividend Date for mandatory convertible preferred stock—$1.50/share payable Feb 2, 2026
• "What Lies Ahead After Breakout Rejection" (Benzinga)—struggled for 300+ days, now in Phase 7 of cycle
• Insider selling: CEO sold $440K

FLO (Flowers Foods):

• Dave's Killer Bread launches new breakfast bars to "Rock Your Reset" (Jan 6)—new product line expansion
• No insider activity

GSK (GlaxoSmithKline):

• Japan approved Exdensur (depemokimab) for severe asthma and chronic rhinosinusitis (Jan 6)—new drug approval
• Pfizer and GSK planning 2026 price hikes on hundreds of branded medicines in U.S.
• No insider activity

BROS (Dutch Bros):

• "A High-Growth Coffee Chain With Long-Term Upside Still Brewing" (Seeking Alpha)—targets 2,029 stores by 2029
• "Liquidity Position Strengthens: A Buffer Against Cost Volatility?" (Zacks)—$706M liquidity buffer
• "My 3 Favorite Stocks to Buy Right Now" (The Motley Fool)—included in top picks
• Heavy insider selling: 10% owners sold $18.7M (Travis Boersma and entities)

LYFT:

• CEO John Risher BOUGHT $100K of stock (Dec 10)—rare insider purchase, bullish signal
• Executives sold ~$1.3M (officers), but CEO buy is notable
• Earnings in 35 days

CYTK (Cytokinetics):

• Grabar Law Office investigating claims on behalf of shareholders—potential legal issues
• Heavy insider selling: Officers and directors sold $4.1M combined
• Earnings in 51 days

ISRG (Intuitive Surgical):

• Heavy insider selling: CEO sold $13.9M, EVP sold $2.7M, directors sold combined
• Earnings in 16 days (Jan 22)—HIGH EVENT RISK
• RSI 70.7—very overbought, late-stage momentum

DGX (Quest Diagnostics):

• Insider selling: CEO sold $916K, director sold $240K
• Earnings in 23 days (Jan 29)—approaching event risk

CIEN (Ciena):

• Insider selling: CEO sold $1.6M
• Earnings in 63 days (low risk)

VRSN (VeriSign):

• Insider selling: CEO sold $521K over multiple transactions
• Earnings in 30 days

Field Notes

Key Metrics Explained:

• RSI(14): Relative Strength Index (0-100 scale). <30 = oversold, >70 = overbought. For buy signals, lower RSI = buying into strength from oversold levels.
• Insider Net (USD): Net insider purchases minus sales over 90 days (P-S only). Negative = selling, positive = buying.
• Days → Earnings: Time until next earnings report. <14 days = high volatility risk, >45 days = lower event risk.
• EMA10: 10-day exponential moving average. Price crossing above = short-term bullish reversal.
• MACD: MACD Line crossing above Signal Line = bullish momentum confirmation.

Sector Rotation Observations:

• Healthcare leads with 6 signals (22%): ISRG, SYK, GSK, LH, DGX, CYTK—defensive rotation into healthcare
• Technology with 9 signals (33%): PANW, AI, FOUR, PTC, CYBR, LYFT, VRSN, CIEN—tech still dominant
• Consumer Cyclical with 6 signals (22%): PVH, AAP, VAC, BROS, RCL, WEN—consumer bouncing from oversold
• Consumer Defensive with 2 signals (7%): CHD, FLO—defensive staples
• Industrials with 3 signals (11%): DE, RRX, MAS—industrial equipment and construction
• Real Estate (NSA), Communication Services (LUMN), Financial Services (BEN)—scattered

Healthcare + Technology = 55% of signals—classic defensive + growth rotation.

RSI Distribution:

• Very Oversold (RSI < 35): 3 signals (11%)—PVH, AAP, VAC
• Moderately Oversold (35-50): 11 signals (41%)—Best risk/reward zone
• Neutral (50-60): 8 signals (30%)—Balanced momentum
• Overbought (60-70): 4 signals (15%)—GSK, SYK, CIEN, ISRG
• Extremely Overbought (>70): 1 signal (4%)—ISRG (RSI 70.7)

Most signals (52%) are in the 35-60 RSI range—healthy pullback bounces with dual confirmation.

Insider Activity Warning:

• BROS: -$18.7M (10% owners dumping)
• ISRG: -$13.9M (CEO selling heavily)
• CYTK: -$4.1M (officers selling)
• AI: -$3.6M (CEO selling)
• DGX: -$1.5M (CEO and director)
• CIEN: -$1.6M (CEO)
• VRSN: -$521K (CEO)
• FOUR: -$440K (CEO)
• PANW: -$142K (director)
• LYFT: +$100K (CEO BUYING)—only insider purchase in the entire list!

Heavy insider selling across most names. Only LYFT CEO is buying. This suggests insiders are taking profits into strength—proceed with caution.

Earnings Risk (< 30 Days):

• ISRG: 16 days (Jan 22)—HIGH RISK: Earnings in 2 weeks + RSI 70.7 + insider selling -$13.9M. Don't hold through earnings.
• RCL: 21 days (Jan 27)—Moderate risk, cruise line earnings
• SYK: 21 days (Jan 27)—Moderate risk, medical devices
• DGX: 23 days (Jan 29)—Moderate risk, healthcare diagnostics
• CHD: 24 days (Jan 30)—Moderate risk, consumer staples
• BEN: 24 days (Jan 30)—Moderate risk, asset management
• LUMN: 28 days (Feb 3)—Threshold risk
• GSK: 29 days (Feb 4)—Threshold risk
• PTC: 29 days (Feb 4)—Threshold risk
• RRX: 29 days (Feb 4)—Threshold risk

10 signals have earnings within 30 days—consider exiting before earnings if unwilling to hold through volatility.

Vlad's Take (EverHint)

Market Backdrop (Jan 6, 2026):
Markets extended gains Tuesday with S&P 500 up 0.53% to 6,944.83 (new all-time high), Nasdaq up 0.43% to 23,547.17, and Dow up 0.97% to 49,462.09. The VIX closed at 14.75 (down 1.67%), signaling low-to-normal volatility—ideal for swing trades. Small-caps outperformed with Russell 2000 up 1.49% to 2,582.90, indicating broad market strength. Treasury yields rose slightly (10Y at 4.179%, up 0.14%), and crypto was mixed (Bitcoin -0.39%, Ethereum +1.84%). Overall: risk-on environment with strong breadth—perfect conditions for dual-crossover setups.

Strategy Commentary:
Today's EMA10 × Price × MACD scan captured 27 buy signals where both price action AND momentum indicators confirmed bullish shifts. With markets hitting new all-time highs and VIX at 14.75, this is an ideal environment for swing trades with technical confirmation.

Four Observations:

1. Healthcare + Tech dominate (55% of signals): This is a defensive + growth rotation. Healthcare (ISRG, SYK, GSK, LH, DGX, CYTK) + Technology (PANW, AI, FOUR, PTC, CYBR, LYFT, VRSN, CIEN) make up 15 of 27 signals. This suggests investors are rotating into growth (tech) and defensive quality (healthcare) simultaneously—classic late-cycle behavior.

2. RSI distribution is healthy: 52% of signals are in the 35-60 RSI range—this is the sweet spot for dual-crossover buys. These are stocks pulling back to oversold/neutral levels, then crossing up with MACD confirmation. The very oversold names (PVH, AAP, VAC) offer best risk/reward if downtrends reverse. The overbought names (ISRG, CIEN, SYK, GSK) are momentum chases—higher risk but potentially higher reward if momentum persists.

3. Heavy insider selling is a red flag: BROS (-$18.7M), ISRG (-$13.9M), CYTK (-$4.1M), AI (-$3.6M), DGX (-$1.5M), CIEN (-$1.6M)—insiders are dumping into strength. The only insider BUY is LYFT CEO (+$100K). This is late-stage behavior. Insiders sell at highs, retail buys breakouts. Use tight stops and don't overstay your welcome.

4. Earnings risk is elevated: 10 of 27 signals (37%) have earnings within 30 days. ISRG has earnings in 16 days + RSI 70.7 + insider selling -$13.9M—this is a triple red flag. If you trade ISRG, exit before earnings (Jan 22). Same for RCL, SYK, DGX (earnings Jan 27-29).

Trading Tips for Dual Crossovers:

Entry Strategy:

• Don't chase today's close. Wait for tomorrow's pullback or consolidation near today's close.
• Use limit orders at or slightly below today's close. Let the stock come to you.
• Confirm volume tomorrow: If stock gaps up but volume is weak, wait for volume confirmation.
• Scale in: Take 50% position on entry, add 25% if stock holds above EMA10 for 2+ days, add final 25% if MACD histogram expands (momentum accelerating).

Position Sizing:

• Start with 1-2% of portfolio per signal. Don't go heavy on dual crossovers—they can fail quickly if momentum doesn't follow through.
• Max 5-7 signals total from the 27. Pick highest-conviction setups (low RSI, no insider selling, >30 days to earnings).
• Diversify by sector: Don't take all healthcare or all tech. Spread across 3+ sectors.

Stop Loss (CRITICAL):

• Tight stops below EMA10: Once price crosses above EMA10, use EMA10 as your stop. If price closes below EMA10, exit—the crossover failed.
• Alternative stop: Use yesterday's low or today's low, whichever is closer. Example for PANW: Close $185.86, today's low likely ~$182. Stop at $181 (just below today's low). Risk = 2.6%.
• MACD reversal stop: If MACD Line crosses back below Signal Line, exit—momentum confirmation failed.
• Move stops to breakeven once stock moves 3-5% in your favor. Lock in gains quickly.

Take Profit:

• Conservative: 5-10% gain (1-2 weeks)—take full profit at EMA10 crossover targets
• Aggressive: 10-15% gain (2-4 weeks)—hold until MACD Line crosses back below Signal Line or price closes below EMA10
• Scale out: Take 50% off at +5-7%, trail stops on remaining 50%

Time Stop:

• Exit if no progress in 1 week. Dual crossovers either work quickly (within 3-5 days) or stall. Don't let them become dead money.
• Exit before earnings if <14 days. ISRG, RCL, SYK, DGX, CHD—exit by Jan 20 if you don't want to hold through earnings.

My Top 7 Picks (Best Risk/Reward):

1. PVH (RSI 31.7, $70.01): Most oversold signal. Apparel brand bouncing from lows. Stop below $68, target $74-76 (+6-9%). Earnings in 83 days (low risk). High risk/reward on downtrend reversal.

2. AAP (RSI 34.8, $41.36): Auto parts retailer bouncing, launched new ARGOS brand. Stop below $39, target $44-45 (+6-9%). Earnings in 50 days.

3. PANW (RSI 41.9, $185.86): Cybersecurity leader bouncing from 14% pullback. "Buy and Hold for the Next Decade" (Motley Fool). Stop below $182, target $195-200 (+5-8%). Earnings in 37 days. Quality name with dual confirmation.

4. LH (RSI 45.3, $260.40): Labcorp crossing up, no insider selling. Stop below $253, target $270-275 (+4-6%). Earnings in 30 days. Above SMA200—uptrend confirmation.

5. DE (RSI 48.3, $485.98): Deere crossing up, no insider selling. Stop below $466, target $500-510 (+3-5%). Earnings in 37 days. Blue-chip industrial with dual confirmation.

6. LYFT (RSI 58.1, $19.86): CEO BUYING +$100K—only insider purchase in entire list. Stop below $19, target $21-22 (+6-11%). Earnings in 35 days. Insider buy = high conviction.

7. GSK (RSI 63.0, $50.56): Japan approved new asthma drug Exdensur (Jan 6)—catalyst. Stop below $49, target $53-54 (+5-7%). Earnings in 29 days. Pharma with new drug approval + dual crossover.

Avoid:

• ISRG (RSI 70.7, earnings in 16 days, insider selling -$13.9M): Triple red flag—overbought + earnings risk + heavy insider selling. If you must trade, exit before Jan 22 earnings.
• BROS (insider selling -$18.7M): 10% owners dumping $18.7M—this is a distribution phase. Avoid.
• AI (insider selling -$3.6M, RSI 43.2, below SMA200): CEO sold $3.6M, stock in long downtrend. Mixed sentiment. High risk.
• CYTK (insider selling -$4.1M, legal investigation): Grabar Law Office investigating shareholder claims. Officers selling heavily. Avoid.
• Low-conviction setups: Signals with RSI > 65 (CIEN, SYK, ISRG) + earnings within 30 days + insider selling. Too many red flags.

Risk Warning:
Dual crossovers can fail quickly if momentum doesn't follow through. Always use stop losses below EMA10 or yesterday's low. If price closes below EMA10 or MACD crosses back below Signal Line, exit immediately—the setup failed. Never risk more than 1-2% of portfolio on any single dual-crossover trade.

📌 If this gave you insight, a quick like, share, or subscribe supports the continued work behind EverHint.

Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/